| Next 10 |
SYBX News and Press, Synlogic Inc.
-
Gainers: Acorda Therapeutics (ACOR) +45%, NuCana (NCNA) +26%, Synlogic (SYBX) +24%, Evoke Pharma (EVOK) +23%, Tiziana Life Sciences (TLSA) +14%.Losers: Zomedica (ZOM) -26%, Forward Pharma (FWP) -15%, Provention Bio (PRVB) -14%, Acutu...
-
Synlogic ([[SYBX]] +1.3%) anticipates clinical proof of concept data in 2021 across its two metabolic programs:SYNB1618 for the treatment of Phenylketonuria ((PKU)):This investigational drug composed of a synthetic biotic medicine is into progression of a proof of concept phase 2 cl...
-
Synlogic Outlines Upcoming Clinical Milestones - Clinical proof of concept data in 2021 anticipated across multiple programs - PR Newswire CAMBRIDGE, Mass. , Jan. 11, 2021 /PRNewswire/ -- Synlogic, Inc. ( Nasdaq: SYBX ), a clinical stage company bringing ...
-
Gainers: Anchiano Therapeutics ANCN +173%, Prevail Therapeutics PRVL +84%, BioCardia (BCDA) +40%, Solid Biosciences (SLDB) +37%, OncoCyte OCX +32%.Losers: Mirum Pharmaceuticals (MIRM) -21%, Mesoblast (MESO) -18%, Rubius Therapeutics ...
-
Apartment Investment and Management (AIV) -84% after spinoff of Apartment Income REIT closes.CooTek (Cayman) (CTK) -13% on Q3 earnings release.Mirum Pharmaceuticals (MIRM) -19% after prices equity offering at $20.Mesoblast (MESO) -15% after it ...
-
AnPac Bio-Medical Science (ANPC) +99% as company makes significant progress in detecting pre-cancer diseases.Arvinas (ARVN) +74% after releasing interim clinical data of PROTAC® protein degraders.Veru (VERU) +57% on positive phase 2 clinical trial results for Enobosarm.Syn...
-
Thinly traded nano cap Synlogic (SYBX) is up 44.2% premarket on announcement of positive results from a Phase 1 study evaluating SYNB1891 has advanced into the combination therapy stage, an investigational drug for the intra-tumoral treatment of solid tumor...
-
Synlogic Announces Advancement of SYNB1891 to Combination Arm Dosing with PD-L1 Checkpoint Inhibitor in the on-going Phase 1 Study for the Treatment of Solid Tumors and Lymphoma CAMBRIDGE, Mass. , Dec. 14, 2020 /PRNewswire/ -- Synlogic, Inc. ( Nasdaq: SYBX )...
-
Synlogic Appoints Michael Heffernan to its Board of Directors CAMBRIDGE, Mass. , Dec. 9, 2020 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the appointm...
-
Synlogic Presents SYNB8802 for Enteric Hyperoxaluria at the American Institute of Chemical Engineers Conference on Microbiome Engineering CAMBRIDGE, Mass. , Dec. 7, 2020 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformat...
Stock Information
MENU
SYBX
SYBX Quote
SYBX Short
SYBX News
SYBX Articles
Get SYBX Alerts
News, Short Squeeze, Breakout and More Instantly...
-
Synlogic Outlines Upcoming Clinical Milestones - Clinical proof of concept data in 2021 anticipated across multiple programs - PR Newswire CAMBRIDGE, Mass. , Jan. 11, 2021 /PRNewswire/ -- Synlogic, Inc. ( Nasdaq: SYBX ), a clinical stage company bringing ...
-
Synlogic Announces Advancement of SYNB1891 to Combination Arm Dosing with PD-L1 Checkpoint Inhibitor in the on-going Phase 1 Study for the Treatment of Solid Tumors and Lymphoma CAMBRIDGE, Mass. , Dec. 14, 2020 /PRNewswire/ -- Synlogic, Inc. ( Nasdaq: SYBX )...
-
Synlogic Appoints Michael Heffernan to its Board of Directors CAMBRIDGE, Mass. , Dec. 9, 2020 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the appointm...
x